AstraZeneca has joined the ranks of pharma companies seeking to bring drugs targeting lipoprotein(a) to market, paying $100 million upfront for rights to a drug developed by CSPC Pharmaceutical. The ...
AstraZeneca has forged a wide-ranging collaboration with Chinese biotech CSPC Pharma that will focus on the use of artificial intelligence (AI) to find new medicines across a range of diseases. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback